Eric P. Winer

The paper analyzes HER2+ breast cancer using multi-platform data to identify molecular predictors of response to neoadjuvant therapy and highlights intra-tumoral heterogeneity and immune exclusion mechanisms.

This study analyzes genomic alterations in a large IBC cohort, finding high TP53 mutation frequency and NOTCH pathway enrichment, but no major genomic differences compared to non-IBC cases.

The paper identifies CD43 as a glyco-immune checkpoint that inhibits human macrophage phagocytosis, showing that O-linked glycosylation and sialylation pathways regulate this process in AML.

This study quantifies cell proliferation in tumors using multiplexed imaging and identifies spatial and temporal patterns of cell cycle regulation.

This study finds that 5% of breast cancers have high tumor mutation burden, more common in metastatic tumors, with APOBEC activity as the most common mutational process and potential benefit from PD-1 inhibitors.